ABVC BioPharma
ABVC
10 hedge funds and large institutions have $305K invested in ABVC BioPharma in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
26% more capital invested
Capital invested by funds: $241K → $305K (+$63.7K)
0.94% less ownership
Funds ownership: 3.15% → 2.21% (-0.94%)
23% less funds holding
Funds holding: 13 → 10 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$17.6K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$15.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$84.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$24K |
| 3 |
VF
Virtu Financial
New York
|
-$9K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$682 |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
-$123 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $111K | +$15.3K | +25,197 | +32% |
|
|
XT
2
XTX Topco
George Town,
Cayman Islands
| $64.1K | +$15.8K | +26,034 | +76% |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $49.8K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $30.7K | +$17.6K | +28,993 | +289,930% |
|
5
Northern Trust
Chicago,
Illinois
| $20.3K | – | – | – |
|
6
State Street
Boston,
Massachusetts
| $13.7K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $12.2K | -$682 | -1,123 | -9% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $2.73K | +$8 | +13 | +0.5% |
|
|
SS
9
SBI Securities
Tokyo,
Japan
| $488 | -$123 | -202 | -31% |
|
|
10
Bank of America
Charlotte,
North Carolina
| $90 | +$2 | +4 | +5% |
|
|
APP
11
Avantax Planning Partners
Dubuque,
Iowa
| – | -$84.9K | -143,968 | Closed |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$24K | -40,743 | Closed |
|
|
VF
13
Virtu Financial
New York
| – | -$9K | -15,935 | Closed |
|
ABVC Hedge Fund Activity: Q1 2025 in Review
10 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q1 2025, worth a combined $305K — up 26% from $241K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ABVC and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was UBS Group, adding an estimated $17.6K. The largest seller was Avantax Planning Partners, exiting entirely with an estimated $84.9K sold.
- 10 institutional investors held ABVC BioPharma (ABVC) as of Q1 2025, down from 13 in Q4 2024.
- Funds reported $305K of ABVC BioPharma stock for Q1 2025, up 26% quarter-over-quarter.
- 0 funds opened new ABVC BioPharma positions in Q1 2025 and 3 closed out, a net change of -3 holders.
- The largest ABVC BioPharma buyer in Q1 2025 was UBS Group, an estimated $17.6K added.
- The largest ABVC BioPharma seller in Q1 2025 was Avantax Planning Partners, an estimated $84.9K sold.
Based on aggregated 13F filings for Q1 2025.